Pieris pharmaceuticals, inc. (PIRS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Jun'14Dec'13
Operating activities:
Net loss

-25,469

-26,754

-17,647

-22,799

-14,058

-9,849

-

66

Net loss for the period

-

-

-

-

-

-

-15

-

Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation

632

570

400

361

307

366

-

384

Right-of-use asset amortization

408

0

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

2,589

-

414

Stock-based compensation

5,374

4,943

3,046

1,905

1,164

571

-

-

Non-cash restricted shares

-

-

-

-

446

-

-

-

Non-cash consulting shares

-

-

-

-

225

-

-

-

Warrants issued in Private Placement

-

-

-

-

-

664

-

-

Other non-cash transactions

69

-75

-293

-49

-

-

-

-

Realized investment gains

1,161

1,651

0

-

-

-

-

-

Deferred tax benefit

0

-164

0

-

-

-

-

-

Foreign currency re-measurement loss

61

-22

-156

0

-

-

-

-

Changes in operating assets and liabilities:
Restricted cash

-

-

-

-

-

-70

-

-114

Accounts receivable

4,055

-12,511

14,469

59

-

-465

-

337

Prepaid expenses and other assets

679

3,939

-1,900

1,020

1,256

921

-

-

Deferred revenue

-28,524

9,308

74,378

3,752

-

-

-

-

Prepaid expenses

-

-

-

-

-

-

-

-1

Other assets

-

-

-

-

-

-

-

-691

Accounts payable

1,257

764

-332

1,360

-90

1,115

-

-549

Accrued expenses and other current liabilities

-914

3,249

2,060

2,063

556

-136

-

-3,846

Lease liabilities

-794

0

-

-

-

-

-

-

Income taxes

-

-

-

-

-

-

-

-14

Net cash provided by operating activities

-

-

-

-14,388

-12,705

-5,065

-

-3,076

Increase (Decrease) in Accounts Payable

-

-

-

-

-

-

0

-

Net cash used in operating activities

-52,467

-1,066

49,754

-

-

-

-15

-

Investing activities:
Purchases of property and equipment

2,462

1,698

1,950

560

620

267

0

49

Proceeds from maturity of investments

63,325

88,358

0

-

-

-

-

-

Proceeds from sale of investments

8,292

22,047

0

-

-

-

-

-

Purchases of investments

59,317

117,582

43,925

0

-

-

-

-

Net cash provided by (used in) investing activities

9,838

-8,875

-45,875

-

-

-

-

-

Financing activities:
Net cash used in investing activities

-

-

-

-560

-620

-267

-

-49

Proceeds from Stock Options Exercised

553

1,000

781

0

10

-

-

-

Proceeds from employee stock purchase plan

369

0

-

-

-

-

-

-

Proceeds from Warrant Exercises

200

300

3,309

0

-

-

-

-

Proceeds from Issuance of Common Stock

-

-

-

-

-

11,963

26

-

Issuance of Common and Preferred Stock, net of issuance costs

30,998

47,211

0

15,221

25,763

-

-

-

Proceeds from director loans

-

-

-

-

-

-

0

-

Net cash provided by financing activities

32,166

48,511

4,090

-

-

-

26

-

Effect of exchange rate change on cash and cash equivalents

-2,144

-1,581

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-12,607

36,989

-

-

-

-

-

-

Issuance of Preferred Stock-series C, net of issuance costs

-

-

-

-

-

7,342

-

-

Proceeds from convertible stockholder loan

-

-

-

-

-

1,210

-

327

Repayment of debt

-

-

-

-

1,157

181

-

-

Net cash provided by financing activities

-

-

-

15,221

24,616

20,333

-

327

Effect of exchange rate change on cash and cash equivalents

-

-

553

-267

-414

-215

-

161

Net increase in cash and cash equivalents

-

-

8,522

6

10,874

14,784

11

-2,637

Supplemental cash flow disclosures:
Accretion of Series C convertible preferred stock

2

0

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

206

71

-

79

Cash paid for income taxes

0

908

0

162

203

-

-

-

Net unrealized gain on investments

14

681

-820

0

-

-

-

-

Property and equipment included in accounts payable

1,235

241

114

22

-

-

-

-

Conversion from debt to equity

-

-

-

-

-

4,380

-

-

Cash received for income taxes

-

-

-

-

-

-

-

17